// App-Quantinova.ai

: Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Researchers

Presenter

  • J. Mark FitzGerald

Principal Investigators

  • Eugene R. Bleecker

  • Andrew Menzies-Gow

  • James G. Zangrilli

  • Paul Metcalfe

  • Ian Hirsch

  • Paul Newbold

  • Mitchell Goldman

Medical Centers

  • Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada,

  • Center for Applied Genetics and Genomics Medicine, University of Arizona School of Medicine, Tuscon, AZ, United States of America

  • Department of Anaesthesia, Royal Brompton Hospital, London, United Kingdom

  • AstraZeneca, Gaithersberg, MD, United States,

  • MedImmune LLC, Gaithersburg, MD, United States of America

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Benralizumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved